Cancellation of state registration. Parlodel®

April 04, 2017

Active substances:

Bromocriptine

Trade names:

Parlodel®

ICD-10:

II.C73-C75.C75.1 Malignant neoplasm of pituitary gland

II.D10-D36.D35.2 Benign neoplasm of pituitary gland

IV.E20-E35.E22.0 Acromegaly and pituitary gigantism

IV.E20-E35.E22.1 Hyperprolactinemia

IV.E20-E35.E28.2 Polycystic ovary syndrome

IV.E20-E35.E28.3 Primary ovarian failure

VI.G20-G26.G20 Parkinson's disease

VI.G20-G26.G21 Secondary Parkinsonism

XIV.N40-N51.N46 Male infertility

XIV.N60-N64.N61 Inflammatory diseases of the breast

XIV.N80-N98.N91 Absence of menstruation, meager and rare menstruation

XIV.N80-N98.N97 Female infertility

Bromocriptine, Parlodel, pituitary neoplasm, acromegaly, infertility, Parkinson's disease, parkinsonism, polycystic ovary

The Ministry of Health of the Russian Federation, in accordance with Article 32 of Federal Law No. 61-FZ of 12.04.2010 "On circulation of medicines", decided to abolish state registration and exclude from the state register of medicinal products for medical use of the medicinal product (registration certificate P N015275 / 01 from 11.08.2008 issued by Meda AB, Sweden):

Parlodel® (trade name of the medicinal product)

Bromocriptine (international non-proprietary or grouping or chemical name)

tablets, 2.5 mg (dosage form, dosage)

Novartis Pharma SpA, Italy Via Provinciale Schito 131,1-80058 Torre Annunziata, Italy (name and address of the location of the manufacturer of the medicinal product)

on the basis of filing an application by the authorized legal entity LLC Meda Pharma to cancel the state registration of the medicinal product.